Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 8 de 8
Filter
1.
Colorectal Dis ; 26(3): 527-533, 2024 Mar.
Article in English | MEDLINE | ID: mdl-38247259

ABSTRACT

AIM: The aim was to estimate the 10-year cost-utility of haemorrhoidectomy surgery with preference-based measures of health using Canadian health utility measures and costs. METHODS: Patients undergoing elective haemorrhoidectomies by general and colorectal surgeons in British Columbia, Vancouver, between September 2015 and November 2022, completed preoperatively and postoperatively the EuroQol five-dimension five-level health-related quality of life questionnaire (EQ-5D-5L). Quality-adjusted life years (QALYs) attributable to surgery were calculated by discounting preoperative and postoperative health utility values derived from the EQ-5D-5L. Costs were measured from a health system perspective which incorporated costs of hospital stay and specialists' fees. Results are presented in 2021 Canadian dollars. RESULTS: Of 94 (47%) patients who completed both the preoperative and postoperative questionnaires, the mean gain in QALYs 10 years after surgery was 1.0609, assuming a 3.5% annual discounting rate. The average cost of the surgery was $3166. The average cost per QALY was $2985 when benefits of the surgery were assumed to accrue for 10 years. The cost per QALY was higher for women ($3821) compared with men ($2485). Participants over the age of 70 had the highest cost per QALY ($8079/QALY). CONCLUSIONS: Haemorrhoidectomies have been associated with significant gains in health status and are inexpensive relative to the associated gains in quality of life based on patients' perspectives of their improvement in health and well-being.


Subject(s)
Hemorrhoidectomy , Quality of Life , Male , Humans , Female , Canada , Cost-Benefit Analysis , Health Status , Quality-Adjusted Life Years
2.
Curr Oncol ; 27(2): 90-99, 2020 04.
Article in English | MEDLINE | ID: mdl-32489251

ABSTRACT

Background: Patient-reported outcomes (pros) are essential to capture the patient's perspective and to influence care. Although pros and pro measures are known to have many important benefits, they are not consistently being used and there is there no Canadian pros oversight. The Position Statement presented here is the first step toward supporting the implementation of pros in the Canadian health care setting. Methods: The Canadian pros National Steering Committee drafted position statements, which were submitted for stakeholder feedback before, during, and after the first National Canadian Patient Reported Outcomes (canpros) scientific conference, 14-15 November 2019 in Calgary, Alberta. In addition to the stakeholder feedback cycle, a patient advocate group submitted a section to capture the patient voice. Results: The canpros Position Statement is an outcome of the 2019 canpros scientific conference, with an oncology focus. The Position Statement is categorized into 6 sections covering 4 theme areas: Patient and Families, Health Policy, Clinical Implementation, and Research. The patient voice perfectly mirrors the recommendations that the experts reached by consensus and provides an overriding impetus for the use of pros in health care. Conclusions: Although our vision of pros transforming the health care system to be more patient-centred is still aspirational, the Position Statement presented here takes a first step toward providing recommendations in key areas to align Canadian efforts. The Position Statement is directed toward a health policy audience; future iterations will target other audiences, including researchers, clinicians, and patients. Our intent is that future versions will broaden the focus to include chronic diseases beyond cancer.


Subject(s)
Delivery of Health Care/statistics & numerical data , Medical Oncology/statistics & numerical data , Neoplasms/therapy , Patient Reported Outcome Measures , Patient-Centered Care/statistics & numerical data , Canada , Delivery of Health Care/methods , Delivery of Health Care/standards , Humans , Medical Oncology/methods , Medical Oncology/standards , Neoplasms/diagnosis , Patient-Centered Care/methods , Patient-Centered Care/standards , Quality of Life
3.
Colorectal Dis ; 22(11): 1658-1666, 2020 11.
Article in English | MEDLINE | ID: mdl-32533887

ABSTRACT

AIM: The aim of this study is to report changes in health-related quality of life attributable to lateral internal sphincterotomy for treatment of anal fissure. There is very little evidence on whether the overall health-related quality of life of patients is detrimentally affected by the condition, or which aspects of self-perceived health status improve after lateral internal sphincterotomy. This study will articulate which aspects of health tend to improve and guide postoperative expectations appropriately. Knowledge gained from this study may also identify gaps in an individual patient's episode of care. METHOD: Patients were prospectively identified when they consented to surgical treatment of their anal fissure and were contacted by phone to participate. Participants completed a number of patient-reported outcomes preoperatively and 6 months postoperatively. Faecal incontinence-related quality of life, pain and depression were measured at both time points. The severity of faecal incontinence was measured at both times. RESULTS: Participants reported high levels of pain preoperatively. Postoperatively, improvement in pain exceeded the threshold of clinical relevance (P < 0.01). Thirty-five per cent of participants reported significant effects of faecal incontinence preoperatively, while 26% did so postoperatively. Participants with multiple comorbidities were more likely to report faecal incontinence postoperatively than preoperatively. CONCLUSION: This study reports that lateral internal sphincterotomy improved pain symptoms without adverse effects on continence. Not all domains of health-related quality of life were similarly positively affected by anal fissure repair.


Subject(s)
Fissure in Ano , Lateral Internal Sphincterotomy , Anal Canal/surgery , Chronic Disease , Fissure in Ano/surgery , Humans , Quality of Life , Treatment Outcome
4.
J Periodontol ; 81(11): 1596-603, 2010 Nov.
Article in English | MEDLINE | ID: mdl-20629547

ABSTRACT

BACKGROUND: Gingival recession remains an important problem in dental esthetics. A new dermal matrix material has been introduced, but its effectiveness has not been studied and compared to current dermal matrix material. The aim of this study is to compare the healing associated with a coronally advanced flap for root coverage in areas of localized tissue recession when using Alloderm (ADM) and Puros Dermis (PDM). METHODS: A split-mouth design was used for this study, with 52 contralateral sites in 14 patients with Miller Class I or III facial tissue recession. Twenty-six sites were treated with coronally advanced flap using PDM, and 26 sites were treated with coronally advanced flap using ADM, all followed for 6 months. Clinical measurements of vertical recession, keratinized tissue, probing depths, and attachment levels were made initially, at 3 months, and at 6 months. RESULTS: Both groups had significant improvement in the amount of recession coverage with means of 2.83 mm for the PDM and 3.13 mm for the ADM. The percentage of root coverage was 81.4% for the PDM and 83.4% for the ADM; differences between the materials were not statistically significant. CONCLUSIONS: Based on the results of this study, there was no statistical or clinical difference in the amount of root coverage, probing depth, or keratinized tissue in coronally advanced flaps for root coverage with either of the two acellular dermal matrix materials. Both materials were successful in achieving root coverage.


Subject(s)
Biocompatible Materials/therapeutic use , Collagen/therapeutic use , Gingival Recession/surgery , Plastic Surgery Procedures/methods , Tooth Root/surgery , Adult , Female , Follow-Up Studies , Gingiva/pathology , Gingival Recession/classification , Gingivoplasty/methods , Humans , Male , Middle Aged , Periodontal Attachment Loss/surgery , Periodontal Pocket/surgery , Root Planing/methods , Surgical Flaps , Suture Techniques
5.
J Periodontal Res ; 37(2): 101-9, 2002 Apr.
Article in English | MEDLINE | ID: mdl-12009179

ABSTRACT

The objective of this study was to use an in vivo model of periodontitis (mouse calvaria) to quantify the effects of local release of secreted human macrophage products, 17beta-estradiol (E2), and proinflammatory lipopolysaccharide (LPS) on histologic bone resorption. Human THP-1 monocytes (106) were converted to macrophage phenotype by 500 ng/ml phorbol 12-myristate- 13-acetate (PMA) and treated as follows: no stimulation or Escherichia coli LPS (10 microg/ml) alone or in combination with a physiologic dose of E2 (100 pg/ml) for 24 h in RPMI/10% FBS, washed extensively, then incubated for 24 h in serum-free media. Supernatant products were concentrated and incorporated into a 4% (w/v) methylcellulose gel. Separate gels were incorporated with the following: LPS (500 microg/animal) alone, high dose of E2 (10 ng/animal) alone, a combination of LPS + E2, or gel only (controls). Loaded or control gels were placed into a polylactic acid occlusive dome, inserted subcutaneously over the calvaria of mature ovariectomized ICR Swiss mice (8 mice x 7 groups x 2 times [5/14 days] = 112 animals), then calvaria were evaluated histologically. Macrophage stimulation with LPS alone, but not LPS in combination with E2, produced supernatants which upregulated osteoclast numbers in the suture area compared to gel controls at 5 days (p = 0.009). The addition of LPS directly to the local delivery gels significantly upregulated osteoclasts in endosteal surfaces compared to gel controls at 5 days (p = 0.024) and at 14 days (p = 0.025). The addition of E2 to LPS down-regulated resorption to a level not different from gel controls at 14 days. This in vivo model appears effective in studying inflammatory bone resorption, which may be inhibited by E2 directly or through its influence on secreted macrophage products.


Subject(s)
Bone Resorption/physiopathology , Estradiol/pharmacology , Interleukin-1/pharmacology , Lipopolysaccharides/pharmacology , Macrophages/metabolism , Receptors, Interleukin-1/antagonists & inhibitors , Sialoglycoproteins/pharmacology , Analysis of Variance , Animals , Bone Resorption/metabolism , Cell Count , Disease Models, Animal , Down-Regulation , Drug Carriers , Drug Delivery Systems , Escherichia coli , Estradiol/administration & dosage , Female , Humans , Interleukin 1 Receptor Antagonist Protein , Interleukin-1/administration & dosage , Lactic Acid , Lipopolysaccharides/administration & dosage , Macrophages/drug effects , Mice , Mice, Inbred ICR , Osteoclasts/metabolism , Polyesters , Polymers , Sialoglycoproteins/administration & dosage , Skull/drug effects , Skull/physiopathology , Statistics as Topic , Statistics, Nonparametric , Tetradecanoylphorbol Acetate/pharmacology , Up-Regulation
6.
Article in English | MEDLINE | ID: mdl-8899772

ABSTRACT

OBJECTIVES: To determine and compare osseous regeneration associated with three guided tissue regeneration membrane types (expanded polytetrafluoroethylene, dense polytetrafluoroethylene, and an absorbable polylactic acid/citric acid ester base) and removal forces required for expanded and dense polytetrafluoroethylene membranes. STUDY DESIGN: Bilateral osseous defects were created in 30 adult rat calvaria; one defect was covered with a test membrane and the other received no membrane (control). After 2 or 4 weeks, forces required for membrane removal from the tissues were electronically determined, and the calvaria removed and decalcified. Sections through the defects were stained and evaluated electronically and microscopically. Data were analyzed statistically. RESULTS: Microscopic evaluation with Mann-Whitney U test revealed that dense polytetrafluoroethylene was associated with significantly greater bone formation than expanded polytetrafluoroethylene (p = 0.02) at 2 weeks and absorbable polylactic acid/citric acid ester base (p = 0.004) at 4 weeks. Electronic evaluation of the linear degree of fill with one way ANOVA and Tukey's test found no significant difference (p > 0.05) among the experimental or the control groups. In addition, the Mann-Whitney U test indicated that removal forces required for dense polytetrafluoroethylene were significantly less than for expanded polytetrafluoroethylene (p = 0.003). CONCLUSIONS: The use of dense polytetrafluoroethylene as a membrane barrier deserves further investigation as it allows osseous regeneration, it is easier to remove from healing soft tissues, and it is inexpensive. A study with larger sample sizes should be conducted.


Subject(s)
Bone Regeneration , Guided Tissue Regeneration/methods , Membranes, Artificial , Analysis of Variance , Animals , Biodegradation, Environmental , Citric Acid , Lactic Acid , Polyesters , Polymers , Polytetrafluoroethylene/chemistry , Rats , Rats, Sprague-Dawley , Statistics, Nonparametric
7.
Diabetes ; 30(10): 887-9, 1981 Oct.
Article in English | MEDLINE | ID: mdl-6974111

ABSTRACT

Approximately 50% of Wistar "BB" rats spontaneously develop overt diabetes mellitus characterized by loss of beta-cells and "insulitis." To define abnormalities of immunoregulation in these rats, we quantitated their major circulating lymphocyte subsets. Independent of the development of diabetes, we found the BB rats to have a markedly increased percentage of circulating B lymphocytes which is secondary to a severe T-cell lymphocytes which is secondary to a severe T-cell lymphocytopenia, with the major circulating T-cell subset reacting with monoclonal antibody W3/25 markedly decreased. This lymphocytopenia is present in every animal studied and contrasted with studies of the nondiabetic Wistar strain from which the "BB" rats were developed.


Subject(s)
Diabetes Mellitus/immunology , Lymphocyte Depletion , T-Lymphocytes/pathology , Animals , Antibodies, Monoclonal , B-Lymphocytes/pathology , Diabetes Mellitus/genetics , Female , Leukocyte Count , Male , Rats , Rats, Inbred Strains
SELECTION OF CITATIONS
SEARCH DETAIL
...